Frequently Asked Questions

You may or may not directly benefit from being in the clinical study. However, the information collected during the BEACON Study may help doctors learn more about the study drug and cutaneous sarcoidosis, which may help others with cutaneous sarcoidosis in the future.

It will not cost you anything to participate in the study. Your travel to and from the study visits can either be arranged on your behalf, or you can be directly reimbursed for your travel. A caregiver may also be eligible for travel-related cost and services. Speak to a member of the study team for more information.

The biotechnology company Priovant Therapeutics is sponsoring the BEACON Study. Priovant Therapeutics is committed to developing targeted therapies for people living with severe autoimmune diseases.

No, being in the study is voluntary. If you decide to join and then change your mind, you can leave the study at any time.

You will be in the study for a little over 1 year.

If you qualify for the study, you will be placed by chance in a treatment group to receive either brepocitinib or placebo.

Investigational medicine means that it has not been approved by country-specific regulatory health authorities to be used for cutaneous sarcoidosis and its use is being allowed for research purposes only.

The placebo looks like brepocitinib but contains no active medicine. This gives researchers something to compare the study drug to, to better understand its effects.

The study doctor will advise you on which medication(s) you will continue to take.

A computer is used to assign study participants to study treatment groups by chance, like flipping a coin. This is called randomization.

Like all medicines, there is a chance for side effects, which are unwanted and unintended effects from a medicine. Your health will be closely monitored during the entire study. It is very important to tell the study doctor if you notice any changes in your health or if anything is bothering you.